AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

MENLO PARK, Calif. & GENEVA--(BUSINESS WIRE)--Jul 23, 2025-

Forgotten drugs could target a neglected disease

Scientists have uncovered how a dangerous parasite uses its human hosts to survive and discovered a potential treatment in an abandoned drug, offering new hope for a neglected disease.

#Combating Neglect The Promise of AN2 Therapeutics and DNDi in Chagas Disease and MAC Lung Disease Treatments,

Chagas disease, caused by the parasite 'Trypanosoma cruzi', represents a significant public health challenge affecting approximately 6 to 7 million people worldwide. This neglected tropical disease can lead to severe chronic complications, including cardiomyopathy and gastrointestinal manifestations, severely impacting patients' quality of life. Recent developments in medicinal chemistry are promising new avenues for effective treatments, partic…